durvalumab,tremelimumab
astrazeneca,pfizer
['durvalumab', 'gastric']
the first results of durigast presented at asco: folfiri durvalumab +/- tremellilumab in 2nd line for advanced esophagogastric adenocarcinoma 
Digestive oncology and immuno-oncology